Immuneering (IMRX) CFO Andrew Gengos Receives 650,000-Share Award

What Happened Andrew Gengos, Chief Financial Officer of Immuneering Corp (IMRX), received a grant/award of 650,000 derivative securities reported as acquired on July 16, 2026. The filing shows $0.00 paid at grant (i.e., no cash exchanged at the time of the award). This is an equity compensation award (stock option-type derivative), not an open-market purchase or sale, so it does not represent an immediate buy or sell of company stock.

Key Details

• Transaction date: 2026-07-16; Form 4 filed: 2026-07-17 (timely filing).
• Reported consideration: $0.00 (award/grant of derivative securities).
• Amount granted: 650,000 shares (derivative — stock option-style award per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: Vesting schedule provided — the option vests monthly over four years with specific percentages (see Context below).
• No indication in the provided data that this was a cashless exercise, sale, gift, or part of a 10b5-1 plan.

Context The filing describes the award as a stock option subject to a detailed monthly vesting schedule: 8.33333% vests on each of the first three monthly anniversaries, 1.6667% on the fourth and subsequent monthly anniversaries up to one year, 3.33333% monthly in the second year, and 0.833333% monthly through the fourth anniversary, with full vesting at four years. Because this is a grant of a derivative security (an option award) rather than an exercised or sold position, it represents future potential equity tied to continued employment rather than immediate realized value.